Piper Sandler Reiterates Overweight Rating on Global Blood Therapeutics (GBT)

Piper Sandler analyst Danielle Brill reiterated an Overweight rating and $120.00 price target on Global Blood Therapeutics (NASDAQ: GBT). Brill believes that GBT is poised to realize Oxbryta's full potential in sickle cell disease. At the current valuation Brill sees opportunity for further upside as the Oxbryta launch moves forward and its "blockbuster potential is realized."

For an analyst ratings summary and ratings history on Global Blood Therapeutics click here. For more ratings news on Global Blood Therapeutics click here.

Shares of Global Blood Therapeutics closed at $68.20 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
• Deutsche Bank Upgrades Target Hospitality (TH) to Buy
• Hims and Hers (HIMS) PT Lowered to $35 at Barclays